Topical treatment of neuropathic pain

International Journal of Pharmaceutical Compounding

Volumn 12, Issue 3, 2008, Pages 183-190

  Vadaurri, Vince ^a  

^a Palliative Pharmacy of Pikes Peak   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; KETOPROFEN; METHADONE; TETRACAINE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CASE REPORT; DRUG FORMULATION; FEMALE; HUMAN; MYALGIA; NEUROPATHIC PAIN; NEUROPATHY; PAIN; TERMINAL CARE; TOPICAL TREATMENT; WOUND;

EID: 77949400519     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bennett GJ. Neuropathic pain: New insights, new interventions. Hosp Pract 1998; 33(10): 95-98, 101-104, 107-110.
2. de Leon-Casasola OA. Multimodal approaches to the management of neuropathic pain: The role of topical analgesia. J Pain Symp Manage 2007; 33(3): 356-364.
3. Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132(3): 237-251.
4. Sawynok J. Topical analgesics in neuropathic pain. Curr Pharm Des 2005; 11(23): 2995-3004.
5. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs 2000; 60(3): 555-574.
6. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000; 288(5472): 1765-1769.
7. Millan MJ. The induction of pain: An integrative review. Prog Neurobiol 1999; 57: 1-164.
8. Doubell TP, Mannion RJ, Woolf CJ. The dorsal horn: State dependent sensory processing, plasticity and the generation of pain. In: Wall PD, Melzack R, eds. Textbook of Pain. 4th ed. Edinburgh: Churchill Livingstone; 1999: 165-181.
9. Carpenter KJ, Dickenson AH. Molecular aspects of pain research. Pharmacogenomics J 2002; 2(2): 87-95.
10. Stein C, Schäfer M, Machelska H. Attacking pain at its source: New perspectives on opioids. Nat Med 2003; 9(8): 1003-1008.
11. Rittner HL, Brack A, Machelska H et al. Opioid peptide-expressing leukocytes: Identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 2001; 95(2): 500-508.
12. Machelska H, Stein C. Immune mechanisms in pain control. Anesth Analg 2002; 95(4): 1002-1008.
13. Kraus J, Borner C, Giannini E et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001; 276(47): 43901-43908.
14. Stein C, Machelska H, Schäfer M. Peripheral analgesic and anti-inflammatory effects of opioids. Z Rheumatol 2001; 60(6): 416-424.
15. Gilron I, Bailey JM, Tu D et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352(13): 1324-1334.
16. Rowbotham MC, Twilling L, Davies PS et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348(13): 1223-1232.
17. Twillman RK, Long TD, Cathers TA et al. Treatment of painful skin ulcers with topical opioids. J Pain Symptom Manage 1999; 17(4): 288-292.
18. Ribeiro MD, Joel SP, Zeppetella G. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage 2004; 27(5): 434-439.
19. Watterson G, Howard R, Goldman A. Peripheral opioids in inflammatory pain. Arch Dis Child 2004; 89(7): 679-681.
20. Krajnik M. Zylicz Z, Finlay I et al. Potential uses of topical opioids in palliative care - report of 6 cases. Pain 1999; 80(1-2): 121-125.
21. Zeppetella G, Paul J, Ribeiro MD. Analgesic efficacy of morphine applied topically to painful ulcers. J Pain Symptom Manage 2003; 25(6): 555-558.
22. Gallagher RE, Arndt DR, Hunt KL. Analgesic effects of topical methadone: A report of our cases. Clin J Pain 2005; 21(2): 190-192.
23. McCarson KE, Krause JE. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin-induced nociception. J Neurosci 1994; 14(2): 712-720.
24. Chen H, Lamer TJ, Rho RH et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc 2004; 79(12): 1533-1545.
25. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 2003; 17(14): 1031-1343.
26. Blackburn-Munro G, Erichsen HK. Antiepileptics and the treatment of neuropathic pain: Evidence from animal models. Curr Pharm Des 2005; 11(23): 2961-2976.
27. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain - multiple drug targets and multiple uses. Curr Pharm Des 2005; 11(23): 2977-2994.
28. Priestley T. Voltage-gated sodium channels and pain. Curr Drug Targets CNS Neurol Disord 2004; 3(6): 441-456.
29. Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des 2005; 11(23): 3005-3011.
30. Lai J, Porreca F, Hunter JC et al. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 2004; 44: 371-397.
31. Argoff CE. New analgesics for neuropathic pain: The lidocaine patch. Clin J Pain 2000; 16(2 Suppl): S62-S66.
32. Galer BS, Jensen MP, Ma T et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002; 18(5): 297-301.
33. Noguchi K, Dubner R, Ruda MA. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience 1992; 46(3): 561-570.
34. Hay C, de Belleroche J. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport 1997; 8(5): 1249-1251.